Saroglitazar: Uses, Side Effects, and How It Works

Saroglitazar is a once-daily oral medication that activates two types of metabolic receptors in the body, giving it a dual ability to lower triglycerides and improve blood sugar control. It was first approved in India in 2013 for diabetic dyslipidemia and has since attracted attention for a broader range of metabolic and liver conditions, including non-alcoholic fatty liver disease and primary biliary cholangitis. Its mechanism sets it apart from older drugs in the same family, and the clinical data so far suggest a safety profile that avoids some of the problems that plagued earlier attempts at dual receptor activation.

How Saroglitazar Works

Your cells contain proteins called peroxisome proliferator-activated receptors, or PPARs. There are several subtypes, but the two most relevant here are PPAR-alpha (α) and PPAR-gamma (γ). PPAR-α is found mainly in the liver and plays a central role in breaking down fats. PPAR-γ is concentrated in fat tissue and helps regulate how the body responds to insulin. Most existing drugs target one or the other: fibrates like fenofibrate activate PPAR-α to lower triglycerides, while thiazolidinediones like pioglitazone activate PPAR-γ to improve insulin sensitivity. Saroglitazar activates both, but with a strong lean toward PPAR-α. In lab assays, its potency at PPAR-α is thousands of times greater than at PPAR-γ.¹

This balance matters. Earlier drugs that tried to combine strong PPAR-α and PPAR-γ activation ran into trouble. Muraglitazar, for example, was shelved after safety signals emerged. Saroglitazar’s design leans heavily on the α side, keeping PPAR-γ activation moderate enough to contribute to insulin sensitization without triggering the degree of fluid retention and weight gain that full-strength PPAR-γ drugs cause.

On the PPAR-α side, saroglitazar ramps up fatty acid breakdown in the liver’s mitochondria and activates genes in peroxisomes that metabolize lipids. On the PPAR-γ side, it nudges fat tissue to store fatty acids more efficiently rather than dumping them into the bloodstream and eventually into the liver. It also increases adiponectin, a hormone released by fat cells that improves insulin sensitivity throughout the body.² The net effect is a drug that tackles high triglycerides and insulin resistance simultaneously rather than forcing you to take two separate medications.

Lowering Triglycerides and Other Lipids

The most established use of saroglitazar is for diabetic dyslipidemia, the pattern of high triglycerides, elevated bad cholesterol, and low good cholesterol that commonly accompanies type 2 diabetes. In the PRESS VI trial, patients who had high triglycerides despite already being on a statin saw their triglyceride levels drop by roughly 45 to 47 percent over 12 weeks with either the 2 mg or 4 mg dose. The 4 mg dose also lowered LDL cholesterol and apolipoprotein B, a marker tied to cardiovascular risk.³

A longer-term observational study followed patients for a full year and found even more dramatic improvements. At 52 weeks, triglycerides had fallen by about two-thirds, LDL cholesterol by roughly 38 percent, total cholesterol by about 45 percent, and non-HDL cholesterol by over half.⁴ These are striking numbers, though it is worth noting they come from an open-label study rather than a placebo-controlled trial, meaning the patients knew they were receiving treatment.

A systematic review pooling data from multiple trials found that saroglitazar 4 mg lowered LDL cholesterol and total cholesterol significantly compared to controls.⁵ When comparing the 4 mg dose to the 2 mg dose, the triglyceride difference between them was not statistically significant, suggesting that for triglyceride lowering alone, either dose gets you most of the way there, though the higher dose appears to have broader effects across other lipid fractions.

Blood Sugar and Insulin Sensitivity

Beyond lipids, saroglitazar has a meaningful effect on blood sugar. In a head-to-head trial against pioglitazone (a pure PPAR-γ drug widely used for glucose control), saroglitazar 4 mg lowered HbA1c, a measure of average blood sugar over two to three months, by about 1.5 percentage points over 24 weeks. That was comparable to pioglitazone’s reduction of about 1.4 points.⁶

A randomized, placebo-controlled study using a gold-standard technique to measure insulin sensitivity directly found that saroglitazar roughly doubled insulin sensitivity over four months, a change that persisted even after adjusting for weight and other variables. Patients on saroglitazar also saw HbA1c fall by about 1.3 points compared to 0.5 points in the placebo group.⁷ The researchers noted that the insulin-sensitizing effect did not simply track with the triglyceride reduction, suggesting that saroglitazar’s moderate PPAR-γ activity directly improves how cells respond to insulin, independent of its fat-lowering actions.⁸

A more recent comparative study found that saroglitazar lowered HbA1c by about 0.8 percentage points, outperforming pioglitazone’s 0.3-point reduction in the same trial, while saroglitazar patients actually lost weight and pioglitazone patients did not.⁹ That combination, glucose lowering without weight gain, is a significant practical advantage.

Non-Alcoholic Fatty Liver Disease and MASH

Fatty liver disease has become one of the most active areas of saroglitazar research. When your liver accumulates too much fat, it can progress from simple steatosis to a more inflammatory state now called metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), and eventually to fibrosis and cirrhosis. Because saroglitazar boosts fat oxidation in the liver while reducing the delivery of fatty acids from fat tissue, it addresses several drivers of the disease at once.

A randomized, double-blind phase 2 trial tested three doses of saroglitazar against placebo in people with fatty liver disease. The 4 mg dose reduced liver enzyme ALT by about 46 percent versus a slight increase in the placebo group. Liver fat content measured by MRI fell by roughly 20 percentage points more in the saroglitazar 4 mg group than in the placebo group. The drug also improved insulin resistance and raised adiponectin levels.¹⁰

A real-world observational study of patients with both fatty liver disease and diabetic dyslipidemia found that 24 weeks of saroglitazar treatment led to significant improvements in liver enzymes ALT and AST, liver stiffness (a proxy for fibrosis), liver fat content measured by ultrasound-based elastography, lipid levels, and HbA1c, all without meaningful changes in weight or BMI.¹¹ However, another single-center experience with 91 patients tempered the enthusiasm slightly: while liver enzymes improved broadly, the reduction in liver stiffness and fat content was statistically significant only in patients who also lost weight during the treatment period.¹² That finding suggests saroglitazar works best for fatty liver disease when paired with weight management rather than as a standalone fix.

Animal studies have provided insight into how the drug affects the deeper stages of disease. In a mouse model of advanced fatty liver disease, saroglitazar reduced liver fat by nearly 80 percent, cut collagen (a fibrosis marker) by about 40 percent, and reversed the upregulation of inflammatory and fibrosis-promoting genes. Overall, it achieved about a 78 percent reduction in a composite disease severity score, substantially outperforming pioglitazone and fenofibrate in the same experiment.¹³ These are animal data and should be interpreted cautiously, but they suggest a plausible path toward reversing, not just slowing, liver damage.

Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is a chronic autoimmune condition where the small bile ducts in the liver are gradually destroyed, leading to bile buildup and progressive liver damage. The main marker doctors track is alkaline phosphatase, or ALP, and reducing it is the primary goal of treatment. Many patients respond to ursodeoxycholic acid, the standard first-line therapy, but a significant minority do not, leaving them with limited options.

A phase 2 trial tested saroglitazar in PBC patients who had an inadequate response to ursodeoxycholic acid. At 16 weeks, the 4 mg dose reduced ALP by about 48 percent and the 2 mg dose by about 40 percent, compared to a 3 percent reduction with placebo. Every single patient in the 4 mg group achieved at least a 15 percent drop in ALP, compared to only about one in six on placebo.¹⁴ These are early-phase results and the study was small (37 patients), but the magnitude of the ALP reduction is eye-catching and has prompted further investigation.

How Saroglitazar Compares to Pioglitazone and Fibrates

Pioglitazone is probably the closest comparator because it is the most widely used PPAR-γ agonist. In a direct comparison, saroglitazar 4 mg lowered triglycerides by 45 percent over 24 weeks while pioglitazone lowered them by only about 16 percent. Saroglitazar also improved several other lipid markers that pioglitazone did not move meaningfully.¹⁵ On the glucose-lowering front, the two drugs are in a similar ballpark, though one newer comparison suggested saroglitazar may edge ahead, particularly in patients with co-existing fatty liver disease.⁹

The biggest practical difference is weight. Pioglitazone is notorious for causing weight gain, often several kilograms over months, largely through fluid retention and increased fat storage. Saroglitazar tends to be weight-neutral or even associated with modest weight loss. In one trial, the saroglitazar group saw BMI decrease significantly while the pioglitazone group showed no change. For patients already dealing with obesity alongside diabetes and fatty liver disease, that distinction can be decisive.

Compared to fibrates, the lipid-lowering power of saroglitazar appears roughly equivalent for triglyceride reduction, but saroglitazar adds the bonus of glucose and insulin-sensitivity improvement that fibrates do not provide. A review of the PRESS trial series concluded that saroglitazar matched fibrates on lipid outcomes while offering better glycemic control without the weight gain typical of PPAR-γ drugs.

Side Effects and Safety

The safety profile of saroglitazar has been reassuring across trials, especially given the troubled history of earlier dual PPAR drugs. A systematic review and meta-analysis covering six studies found no serious adverse events, including no liver toxicity or kidney toxicity, in any clinical trial. The mild side effects that did occur, mainly digestive issues like dyspepsia and gastritis, along with occasional fever, showed up in roughly 10 to 17 percent of patients taking saroglitazar, which was actually better than rates in control groups of up to 20 percent.⁵

One caveat from that same analysis: the 4 mg dose was associated with a small but statistically significant increase in serum creatinine compared to the 2 mg dose. While this did not cross into clinical concern in any trial, it is the kind of finding that warrants ongoing monitoring, particularly in patients who already have some degree of kidney compromise. A large real-world study in India stratified patients by kidney function and found that overall kidney filtration rates remained stable across all groups during treatment, with adverse events being uncommon. Weakness (asthenia) occurred in about 2 percent of patients, and fever in about 1 percent.¹⁶

An important pharmacokinetic detail underlies the kidney safety story. Saroglitazar is absorbed quickly, reaching peak blood levels within about an hour. Its half-life is roughly five to six hours, short enough that it does not accumulate with daily dosing. And it is not eliminated through the kidneys at all; instead, it is cleared through the liver and bile.¹⁷ This non-renal elimination makes it a potentially useful option for patients with impaired kidney function who cannot tolerate some other lipid-lowering agents, though dedicated studies in severe kidney disease are still limited.

Use in HIV-Associated Lipodystrophy and Rare Metabolic Conditions

Antiretroviral therapy for HIV often causes a metabolic side effect called lipodystrophy, which includes abnormal fat redistribution and dangerously high triglycerides. An exploratory trial in this population found that saroglitazar 4 mg lowered triglycerides by about 45 percent over 12 weeks, cut VLDL cholesterol by roughly 46 percent, and raised HDL (good) cholesterol by about 35 percent.¹⁸ The study was small and open-label, but the results are meaningful for a population with limited treatment options and a high risk of pancreatitis from extreme triglyceride levels.

Case reports have also documented saroglitazar’s use in congenital generalized lipodystrophy, an extremely rare genetic condition where the body has virtually no fat tissue, leading to severe insulin resistance and sky-high triglycerides from childhood. In at least one published case, adding saroglitazar to a regimen of pioglitazone, metformin, omega-3 fatty acids, and insulin resulted in significant improvement in both lipid and blood sugar levels.¹⁹ These niche applications highlight the drug’s versatility in conditions driven by lipid and insulin dysregulation.

Where Saroglitazar Stands Globally

Saroglitazar was developed by Zydus Cadila, an Indian pharmaceutical company, and received approval from the Drug Controller General of India in 2013, making it the first-in-class PPAR α/γ dual agonist to reach the market anywhere in the world. Its approved indication in India is for diabetic dyslipidemia not adequately controlled by statins alone. It has since been prescribed off-label for fatty liver disease in India as well, supported by the clinical data described above.

Outside India, the drug does not yet have regulatory approval. Clinical trials for fatty liver disease and primary biliary cholangitis have been conducted in the United States and elsewhere, but the path to approval in markets like the US and Europe involves larger phase 3 trials and longer follow-up. The phase 2 trial in fatty liver disease was promising enough to generate interest, and the PBC data from the EPICS trial have been noted by hepatologists seeking alternatives for patients who fail ursodeoxycholic acid. Still, it is fair to say that for most readers outside India, saroglitazar remains a drug on the horizon rather than one available at their local pharmacy.

Practical Considerations for Patients

If you are prescribed saroglitazar, a few things are worth knowing. The standard dose is 4 mg once daily, typically taken before meals. The drug works quickly in terms of absorption, but the metabolic effects build over weeks. Triglyceride changes tend to show up within six to twelve weeks, while improvements in HbA1c and liver enzymes may take longer to plateau.

You should not expect saroglitazar to replace all your other medications. In most trials, it was used alongside existing therapy, often a statin, metformin, or both. Its strength is filling the gap that statins leave in patients with persistently high triglycerides and poor glucose control. For fatty liver disease, the evidence suggests it works better when combined with lifestyle changes, particularly weight loss, rather than as a pill you take instead of exercising or adjusting your diet.

The lack of weight gain is one of the most patient-relevant features. If you have been on pioglitazone and struggled with increasing weight or swelling, saroglitazar offers a pharmacological alternative that works through overlapping pathways without the same metabolic penalty. However, switching medications is a conversation for your prescribing doctor, not a decision to make based on trial summaries alone.

Because saroglitazar is eliminated through the liver rather than the kidneys, your doctor may consider it particularly if you have mild to moderate kidney impairment. That said, regular monitoring of liver enzymes is standard practice, both because the drug is liver-metabolized and because many patients taking it already have underlying liver conditions. The creatinine signal seen at the 4 mg dose in pooled analyses, while modest, means periodic kidney function checks are reasonable even though the drug does not rely on the kidneys for clearance.